Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) CEO Sanj K. Patel Sells 872 Shares

Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) CEO Sanj K. Patel sold 872 shares of Kiniksa Pharmaceuticals stock in a transaction on Friday, October 9th. The shares were sold at an average price of $21.00, for a total transaction of $18,312.00. Following the completion of the transaction, the chief executive officer now owns 872 shares in the company, valued at $18,312. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of Kiniksa Pharmaceuticals stock opened at $18.41 on Friday. Kiniksa Pharmaceuticals Ltd has a 52-week low of $5.01 and a 52-week high of $28.67. The company’s 50-day simple moving average is $16.85 and its 200-day simple moving average is $19.58. The firm has a market cap of $1.25 billion, a price-to-earnings ratio of -8.37 and a beta of -0.13.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.02). Equities analysts forecast that Kiniksa Pharmaceuticals Ltd will post -2.3 EPS for the current fiscal year.

A number of research analysts have commented on KNSA shares. Zacks Investment Research lowered shares of Kiniksa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 1st. BidaskClub upgraded shares of Kiniksa Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, October 10th. Goldman Sachs Group lifted their price objective on shares of Kiniksa Pharmaceuticals from $20.00 to $33.00 and gave the company a “buy” rating in a research note on Tuesday, June 30th. ValuEngine lowered shares of Kiniksa Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, July 2nd. Finally, Wedbush boosted their price target on shares of Kiniksa Pharmaceuticals from $30.00 to $38.00 in a research note on Monday, June 29th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $30.50.

A number of hedge funds have recently added to or reduced their stakes in KNSA. Bank of New York Mellon Corp boosted its holdings in Kiniksa Pharmaceuticals by 4.3% during the first quarter. Bank of New York Mellon Corp now owns 48,222 shares of the company’s stock worth $747,000 after buying an additional 1,998 shares in the last quarter. Russell Investments Group Ltd. purchased a new stake in Kiniksa Pharmaceuticals during the first quarter worth about $34,000. JPMorgan Chase & Co. boosted its holdings in Kiniksa Pharmaceuticals by 94.2% during the first quarter. JPMorgan Chase & Co. now owns 8,895 shares of the company’s stock worth $137,000 after buying an additional 4,314 shares in the last quarter. Citigroup Inc. boosted its holdings in Kiniksa Pharmaceuticals by 41.1% during the first quarter. Citigroup Inc. now owns 3,946 shares of the company’s stock worth $61,000 after buying an additional 1,149 shares in the last quarter. Finally, BNP Paribas Arbitrage SA boosted its holdings in Kiniksa Pharmaceuticals by 101.9% during the first quarter. BNP Paribas Arbitrage SA now owns 4,526 shares of the company’s stock worth $70,000 after buying an additional 2,284 shares in the last quarter. 31.04% of the stock is currently owned by hedge funds and other institutional investors.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis.

See Also: What is the Russell 2000 Index?

Insider Buying and Selling by Quarter for Kiniksa Pharmaceuticals (NASDAQ:KNSA)

Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.